Despite the recent buzz, the effort to reduce animal testing in favor of NAMs has been underway for years. The VQN falls ...

A new Caribbean company has emerged to enter the increasingly crowded T-cell engager space. | A new Caribbean company has ...

Baxter saw its stock price plunge by more than 20% after it lowered its revenue projections for the remainder of this year, ...

Sanofi is handing over $130 million upfront for the China rights to Arrowhead Pharmaceuticals’ rare metabolic disease ...

Allogene Therapeutics has reported a patient death tied to its anti-CD52 monoclonal antibody used for lymphodepletion in its ...

After the surprise departure of longtime CEO Lars Fruergaard Jørgensen in May, Danish pharma giant Novo Nordisk didn’t take ...

A phase 3 trial of Spine BioPharma’s chronic low back pain candidate has missed its primary endpoint. But, with the biotech pinning the failure on a “very high sham control response,” management plans ...

D Molecular Therapeutics has posted 60-week data on a gene therapy, providing evidence of durability in diabetic macular edema and sending its stock up more than 40% in premarket trading.

A PD-L1xVEGF bispecific antibody from China’s ImmuneOnco Biopharmaceuticals has shown early promise in shrinking lung tumors, ...

AbbVie is ending development of an IL-1 asset as a monotherapy in ulcerative colitis (UC) after a phase 2 study revealed ...

AbbVie has reportedly added Gilgamesh Pharmaceuticals to its shopping list. | AbbVie has reportedly added Gilgamesh ...

After taking on the title of president earlier this year, Dexcom’s Jake Leach will be stepping into the role of CEO at the ...